Author year | Objective |
---|---|
Kahn 2006 [33] | To explore the efficacy (stroke, myocardial infarction and death) of beta blockers in “younger”(< 60 years) and “older” (≥ 60 years) patients. |
Results: | |
1. Beta blockers compared to placebo or no treatment 1 (5 trials and n = 8019 patients, range mean age 65 to 75.7 years) | |
Primary outcome: composite cardiovascular outcome of death, nonfatal myocardial infarction or nonfatal stroke | Beta blockers´ benefits were not found in trials enrolling older patients RR 0.89, 95% CI 0.75–1.05, based on 1115 events in 8019 patients. |
Death | RR 0.91, 95% CI 0.74–1.12 |
Nonfatal myocardial infarction | RR 0.98, 95% CI 0.83–1.16 |
Nonfatal stroke | RR 0.78, 95% CI 0.63–0.98 |
Heart failure | RR 0.54, 95% CI 0.37–0.81 |
2. Beta blocker compared to other antihypertensive agents 1 (7 trials and n = 87,180 patients, range mean age 60.4 to 76 years) | |
Primary outcome: composite cardiovascular outcome of death, nonfatal myocardial infarction or nonfatal stroke | Beta blockers were associated with a higher risk of events than were other antihypertensive agents (7405 events, RR 1.06, 95% CI 1.01–1.10). |
Death | RR 1.05, 95% CI 0.99–1.11 |
Nonfatal myocardial infarction | RR 1.06, 95% CI 0.94–1.20 |
Nonfatal stroke | RR 1.18, 95% CI 1.07–1.30 |
Heart failure | RR 0.98, 95% CI 0.87–1.11 |